Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jury Awards $12.5 Million In Damages In Ethicon Pelvic Mesh Case

This article was originally published in The Gray Sheet

Executive Summary

The jury in the first pelvic mesh case to be heard in Philadelphia’s Court of Common Pleas found that Ethicon failed to warn physicians of the risks of Prolift Pelvic Mesh and that the mesh’s design was defective. It awarded the plaintiff $5.5 million in compensatory damages and $7 million in punitive damages. Ethicon plans to appeal.

You may also be interested in...



Jury Awards $13.5 Million In J&J Pelvic Mesh Personal Injury Suit

Ethicon plans to appeal the verdict, which includes $10 million in punitive damages and $3.25 million in compensatory damages, but some observers speculate that the size of the award might encourage more settlements.

Mesh Lawsuit Claims Boston Scientific Smuggled Counterfeit Product Out Of China

The proposed class-action complaint accuses the manufacturer of smuggling counterfeit plastic out of China for use in its transvaginal mesh products. But Boston Scientific says the case is without merit.

J&J Triumphs In First Prosima Trial

A Dallas jury ruled in favor of Johnson & Johnson subsidiary Ethicon in a pelvic mesh product liability suit on Monday, marking a win in the first case to specifically involve the Prosima product.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel